The Growth of Cancer Treatment Research with Clay Siegall

Clay Siegall has been working to improve the lives of cancer patients for years. As the CEO of Seattle Genetics, Siegall has overseen numerous innovations in cancer research and treatment development. Notably, Seattle Genetics was the first developer of antibody-drug conjugates (ADCs), comprising of such treatments as Adcetris (brentuximab vedotin). This treatment earned FDA approval in 2011. Adcetris is currently available in over 60 countries with no plans to stop expanding to help cancer patients worldwide. This is just one of 20 ADC’s that are currently in development with Seattle Genetics.

In addition, Clay Siegall has played a part in fundraising over $1.2 billion dollars in both private and public funding for of Seattle Genetics. This money has allowed them to continue to research cutting-edge technology and innovative new treatments to improve cancer patient’s quality of life worldwide. As CEO, Siegall has assisted with getting Seattle Genetics joined into several licenses partnerships for our ADC technology, with notable corporations such as Astellas, Genentech (Roche), AbbVie, GlaxoSmithKline, and Pfizer.

Since co-founding Seattle Genetics in 1998, Clay Siegall has left his mark on the industry. After graduating with a Ph.D., Genetics from George Washington University and a B.S., Zoology from the University of Maryland Siegall moved on to gain further experience with Bristol-Myers Squibb Pharmaceutical Research Institute and National Institutes of Health, National Cancer Institute. Unlike the standard of the time, instead of focusing cancer research on indiscriminate chemotherapies, he foresaw a future in cancer treatments by developing targeted therapies, an underdeveloped option at the time.

To date, he is the author of over 70 scientific publications and 15 patents dedicated to cancer research. He was also named Alumnus of the Year for Computer, Math and Natural Sciences by his alma mater, the University of Maryland in 2013 and Entrepreneur of the Year in 2012 by 2012 Pacific Northwest Ernst & Young. He also sits as Director of several prestigious boards with Washington Roundtable, Alder BioPharmaceuticals, and Ultragenyx Pharmaceutical.

Posted in CEO

Leave a Reply